NCT01206660已完成3 期
A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Clinical Success ITT
研究概览
简要总结
The objective of this study is to demonstrate that desoximetasone 0.25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or non-pregnant, non-lactating female 18 years of age or older.
- •Have a definite clinical diagnosis of stable plaque psoriasis involving ≥ 10% of the body surface area (BSA).
- •Have a combined total lesion severity score (TLSS) of ≥ 7 for the Target Lesion.
- •Have a plaque elevation score ≥ 3 of (moderate) for the Target Lesion.
- •The Target Lesion must have an area of at least 5 cm².
- •Have a Physicians Global Assessment (PGA) score of 3 (moderate) or 4 (severe) at baseline for the overall disease severity.
排除标准
- •Patient has current diagnosis of other types of psoriasis other than stable plaque psoriasis (i.e. acute, guttate, erythrodermic, exfoliative or pustular psoriasis) or has psoriasis of any kind of the face or scalp that will require active treatment during the study. Nonprescription antipsoriatic shampoos will be allowed during the study when applied solely to the scalp.
- •Patient has a history of psoriasis that has been unresponsive to topical corticosteroid therapy.
- •In the Investigator's opinion, the patient has other dermatological conditions, such as atopic or contact dermatitis, that may interfere with the clinical assessments of the signs and symptoms of psoriasis.
- •Patient has a history of allergy or sensitivity to corticosteroids or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the patient or the results of the study.
- •Patient has been treated within 12 weeks (or five half lives, whichever is less) prior to the first dose of study drug with any biological therapies for psoriasis.
- •Patient has received any systemic steroids within 4 weeks of the first dose of the study drug. The use of inhaled or intranasal corticosteroids is acceptable as long as usage has been stable for at least 2 weeks prior to the first dose of study drug and will be continued during the study.
- •Patients who have used any topical antipsoriatic agents of any kind or any topical corticosteroids for any reason within 2 weeks prior to first use of study drug. Nonprescription antipsoriatic shampoos used only on the scalp will be allowed during the study.
- •Receipt of any drug as part of a research study within 30 days prior to first dosing.
研究组 & 干预措施
Desoximetasone Spray 0.25%
Experimental
Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
干预措施: Desoximetasone Spray 0.25% (Drug)
placebo
Placebo Comparator
Placebo administered to affected area twice a day for 28 days
干预措施: placebo (Drug)
结局指标
主要结局
Clinical Success ITT
时间窗: 28 days
A patient is considered a Clinical Success if the Physician's Global Assessment (PGA) is 0 (clear) or 1 (almost clear).
Treatment Success
时间窗: Day 28
A patient is considered a Treatment Success for the Target Lesions if the target lesion has a score of 0 or 1 on the Target Lesion Severity Score (TLSS) for each the three signs and symptoms (erythema, scaling and plaque elevation).
次要结局
- Physician's Global Assessment (PGA) of Psoriasis Score at Day 28.(Day 28)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis StudyPsoriasisNCT01043393Taro Pharmaceuticals USA24
Unknown
3 期
Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp PsoriasisScalp PsoriasisNCT02749656Siriraj Hospital105
已完成
2 期
Dexamethasone Iontophoretic Patch for the Treatment of Pain Associated With Lateral EpicondylitisLateral Epicondylitis(Tennis Elbow)NCT00794976Travanti Pharma Inc.216
已完成
1 期
Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior UveitisNon-Infectious Anterior UveitisNCT02309385Aciont Inc44
招募中
4 期
Evaluating the Effect of Intravenous Dexamethasone on the Duration of Spinal Anesthesia After Cesarean DeliverySpinal AnesthesiaDexamethasoneNCT05731960IWK Health Centre192